Are Medical Stocks Lagging Amedisys (AMED) This Year?

Amedisys (AMED), with a Zacks Rank #2 (Buy), has outperformed the medical sector year-to-date, returning 3.1% versus the sector's -6.8%, driven by a 1.5% increase in its full-year earnings estimate over the past quarter. BrightSpring Health Services (BTSG), also with a Zacks Rank #2 (Buy), has significantly outperformed with a 34.6% return year-to-date, supported by a 23.8% increase in its current year EPS estimate over the last three months, suggesting these stocks warrant attention from investors in the medical sector.

Analysis

The Medical sector, currently ranked #5 by Zacks Sector Rank, has broadly underperformed, evidenced by an average year-to-date loss of 6.8%. In contrast, Amedisys (AMED) has demonstrated resilience and positive momentum, achieving a 3.1% year-to-date return. This outperformance is supported by a Zacks Rank of #2 (Buy) and a 1.5% increase in its full-year consensus earnings estimate over the past quarter, indicating improving analyst sentiment and a more positive earnings outlook. AMED, operating within the Medical - Outpatient and Home Healthcare industry which itself has gained 2.6% year-to-date, is thus performing better than both the broader sector and its specific industry peer group. BrightSpring Health Services (BTSG) has shown even more significant outperformance, with its stock returning 34.6% year-to-date. BTSG also carries a Zacks Rank #2 (Buy), and its consensus EPS estimate for the current year has seen a substantial 23.8% increase over the past three months. BrightSpring Health Services, belonging to the Medical Services industry that has declined 5.5% year-to-date, is therefore substantially outpacing both the wider Medical sector and its own industry segment, highlighting strong company-specific drivers.

Key Decisions for Investors

• Investors should evaluate Amedisys and BrightSpring Health Services for potential inclusion or overweighting in portfolios, given their significant year-to-date outperformance of 3.1% and 34.6% respectively against a declining Medical sector.
• The Zacks Rank #2 (Buy) for both companies, coupled with positive earnings estimate revisions for AMED (+1.5% full-year) and BTSG (+23.8% current year EPS), suggests strong underlying fundamentals and a potentially favorable short-term outlook that warrants attention.
• Continued monitoring of analyst sentiment, subsequent earnings estimate revisions, and relative strength within their respective sub-industries (Medical - Outpatient and Home Healthcare for AMED, Medical Services for BTSG) is crucial to confirm sustained momentum and validate investment theses.